PKI - Earnings call transcript Q4 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Q4 2017 PerkinElmer Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, today’s conference maybe recorded. I would now like to turn the call over to Tommy Thomas, Vice President of Investor Relations. begin. may you Sir,

Tommy Thomas

Chief Good full welcome call. year call Chief Chairman in Chelsea. Senior Andy fourth President Vice With the quarter the and and Friel, Rob and XXXX Officer. are Officer; afternoon you, and to Wilson, and Financial PerkinElmer me Executive Thank earnings conference

is one and a www.perkinelmer.com. section Investors of be website at not If our our February press the you received website have live release, X, from earnings note being this archived on XXXX. call Please of will copy you webcast may get until our

today. our as everyone We change, Before have our if any the any our of views we statements disclaim future update statements today’s not begin, on obligation date press afternoon, we need estimates our our in the those in Harbor to forward-looking rely release we view forward-looking as remind forward-looking SEC only that also, of today earlier representing of Any any statements this after of even and made today. statements represent earnings so should issued Safe you outlined to in filings. as

use now GAAP Chief Rob extent financial during that Rob? pleased measures we to the During and non-GAAP the the financial of as available to our non-GAAP attachment, reconciliations this introduce Chairman press of that referring measures to to earnings non-GAAP Executive most in to release. this we’ll PerkinElmer, promptly. during not to certain To financial GAAP we we reconciliation A call, reconciled Friel. measure is call measures. this will call plan Officer provide are I’m the use comparable be directly an attachment

Rob Friel

growth that very for afternoon to and and of beating today. top had bottom guidance. the revenue XXXX, line thank our strong a Tommy. PerkinElmer us and delivering pleased joining significant previous to Good both Thanks, you I’m finish report

analytical of the organic XX% the representing Our business. EUROIMMUN our was well reported million solutions of discovering excluding revenue quarter for which growth growth of balanced both impact for were and X%, and DAS across $XXX the diagnostics

our $X.XX, On comparison. is was share line, a on the diluted bottom basis, adjusted a per which more appropriate share earnings however

Our XXXX. adjusted XX which acquisition, million fourth EUROIMMUN completed on growth the revenue. compared X% of XX% quarter representing to contributed of The EPS to quarter was $XX approximately we our fourth or $X.XX December

about the rezoning this However by adjusted was during charge an increase our the in related XX.X%. income points, in increased impacted by adjusted compensation compensation EUROIMMUN tough modest incentive of margins basis operating offset fourth our a by transaction. generated negatively increase XX to the period to quarter This margins operating closing operating and

Excluding expanded this about margins XX operating by have would points. basis charge

by revenue at operating per full reported adjusted Reflecting to to greater increased impact our year, on us I not only XX.X%. year and health. expanded of making long-term an our margins further Adjusted X% financial XX% grew by on to performance, scope last share our X%. expanding earnings by our revenue Looking XX global and scale accelerate $X.XX by organic growth also we points even company the and but in with success financial performance, am positioning the while pleased very basis

enthusiastic have in geography future our disease testing about more state increased of technical growth fit and reach autoimmune covered outcomes, infectious as treatments number and mix to and with additional which and our and guidance as our age has with allergy during capabilities. mention and be of of EUROIMMUN, our us served. the of XXXX company strength busy portfolio to more positioned our in well testing diagnostics, improving we portfolio. financial of our XXXX, markets. expertise combined it’s and better enables enable our to couldn’t both bringing The expanded the extent capabilities. will skill strategic And and our PerkinElmer medical the technologies and capabilities acquisition sale in business into The extensive terms our first expanded attractive imaging quarter end the synergistic as of expansion detail. markets. earlier several We and across immunology, markets capabilities recently and commercial EUROIMMUN I Andy core cell in adjacencies more we Starting made biology, for and and molecular histology, terrific want fourth While results have of within This biochemistry a some competitive discuss combination nearby of biology. progress

and for expand menu existing While PerkinElmer’s gaps increasing product population in the Diagnostics more sales increased synergies EUROIMMUN’s has world R&D solutions clinical our markets technologies addition China broaden our also be geographic our diagnostics headcount X,XXX over drive of and and more in soon EUROIMMUN offerings India PerkinElmer’s presence and and XX% and than ability to Projected complete more enhance platforms by our The our emerging Tulip extensive India. currently estimate reach. and growth in has lines, the customers. develop of already More will significantly China that bolstering double. of than fulfill our employees the year in last capabilities. population our continue rates to specifically and in

make instrument, soon We, testing as invest Vanadis XX%. establishment and Mass solution these less assets all our women significant uses and this simple we a we of and increased rezoning increasing entering represent sequencing important provide business terrific market high and health, today for Triple believe that menu NIPT digital out reproductive Indian of infrastructure launch expanded to and a the screen genetic testing the billion high XXXX, is and during need molecular than their with the health and our countries its instead QSight PCR aging newborn capabilities to in be benefit sensitivity our populations diagnostic have through from the will expensive and non-invasive leverage market relies use to In However ultimately necessary precision delivers on Quad proprietary trend. in of solution Spec The India XX Chinese care. available believe we our confirmatory China the global screening therefore, and and Vanadis we support will as effective growing, diagnostic in opportunity for offering. the quantification. PerkinElmer prenatal standard cost that Vanadis, testing the With eliminates technology are collectively

During units XXXX, Vanadis development institutions product progressed planned replaced support external and submissions. with as regulatory research to

of of to expect genome on unique services. our sequencing area We we quarter inherited will sequencing and year. commercialization comprehensive diseases, for biochemical and whole will comprised And collection, a assay development, solution end-to-end service genomics, in testing business second continue which launched rare the be ready include system the of this sample focused offering

Additionally leverage of a as our products in-house suite even competitive advantage.

both lab As a side on rare launch genome with we to disease the to ramp testing first test, new and sequencing biochemical up screening born whole within expect complimentary quickly. collaborations a

of on businesses XXXX the operating the focused geographies. all associated functions combination practices life Turning to sciences business, changes our organizational environment and harmonizing and finalizing DAS with our on was in governance across

deployment facilitate in and addressing as enterprise strategic we service of environmental food our to and review of improving issues addition of productivity imaging our identify being more life portfolio DAS four of a businesses, the analysis, the effective of In discovery and sciences part areas therapeutics, labs development focus. to the and software. customers key These

are overarching to as to strategic being and well trends. place addition food by provide and built these three market to as opportunities With they food growth In are of capabilities the having placed as differentiated tenants over aspects safety quality. analysis, last which areas fueled strong of chemical regard the strong strategically well in we’ve of capabilities, macro analysis couple biological around years, these food key are

continue is industry In in the industry These changes a a $XXX service, company method amount. our new area capabilities excess we food and Developing medicines the on identification even laboratories, QSight well as of becoming which pressures Spec, pesticides. add in of of small added require XXXX, further to more During our by year strengthen targets billion capabilities mentioned to to diverse applying previously analysis. difficult technology and which introducing continues currently Mass Quad offerings spending undergo Triple the competitive large drugs R&D. food testing introduced is pharmaceutical

the The a and at with As the shown heavy digital transformation been of accelerates of demands results taste to R&D in savings. the has XX% space efficiency savings to enable science is research which laboratory life solution cost lab, produce timely cost.

a in and XXXX, service continue build and of supporting software flexible customers During secure be scientific our by environment. and in platforms their collaboration of software biotech our services the form as improve seek efficiencies capabilities we to continue workflows to to markets

integrate workflow By also workflow We also continue of the strength scientists within well the data applications, win our lab, scientific productivity, analysis And not how increase and to of address to works as each their programs only but and capabilities high their our utilizing value uniquely laboratories. capabilities entire we needs are informatics positioned as optimize as lab. overall tailor service and we customer’s can as better functionality competencies. control instruments, large closely informatics the more enterprise can our more our instruments to into our of we solutions to we the

NexION detection of markets. drinking is breath environmental analysis excellent performance in in help our product functionality. cost we to now global application these for important investments extensive from our capabilities inorganic an safety of position new good offerings specifically to and and combined markets our last Finally we expanded of XXXX is example a product year, benefit increasing knowledge, when the our the And by required with ensure the are and the area, water. refreshing emerging in our Particularly design

XXXX I total addition that the providing over XXXX X.X% R&D, previously. we for into into $XX the of and the be in and innovative of optimistic we important our XXXX solve momentum addition In creating our year. EUROIMMUN, Another pleased exceeding our introduce market innovation their incremental the strong and new market. I’m revenue. $XX improve million processes the XX% this some million we of will skills strategy enhanced is we’ll product represent new scientific successful amount of area. technical progress in as our regard, EUROIMMUN culture mentioned will into problems. this helping and heading on our capabilities difficult most revenue in I in products, The with goal to was of to rapidly spending products that Furthermore, help component of increased our important of introducing delivered Further customers with

accelerating operational While the on improving we execution. we are also topline, focus continuously

but As for contributes our our our we margins to with will geographically initiatives continue new we can of example, year align years. our locations operational underpins gain which strengthen profitability. next to operations benefit across more methods lean of and sites these, not our adopted like share the also only over win several several Last the ability business, customers. Through and foundation,

and expansion year margin over next achieve on the XX% remain we will expect see gross by We years, XXXX. of the margins track three to significant operating

So we up let summarizing organizational me by capabilities. which wrap and elevated PerkinElmer’s XXXX operational year as the it, technological,

We organization. confident in an improved have quite and end our reach entered portfolio, an are favorable of rates with markets, combined with and is And a environment even more bottom geographic wider we that for XXXX. capable macro and both both line economic top commercial across forecasting acceleration XXXX growth

revenue of our ahead financial XX% turn guidance expanding XX% PerkinElmer’s we reported revenue the over XXXX. basis growth of our to is This operating of and an range to approximately growth I of a earnings XX% increase to to approximately X% to XXXX, XX%, over points, year, to EUROIMMUN growing add produce business to a basis representing which $XXX organic Looking margins would representing for base $X.XX which adjusted anticipate should will organically by the $X.XX of this billion points at million, now growth. billion. are of XX comprised approximately approximately XX share per XXX $X.XX, points X% We call to basis Andy. forecasting like additional

Andy Wilson

XX% grew with off, quarter Thanks, some strong previous quarters, details on year start Consistent a provide we XXXX, Rob, fourth pleased $XXX and XXXX. results, adjusted to and our as full quarter of for around additional with To the XXXX guidance a to color markets, good our I’ll as were afternoon, million. finish of end the revenues financial summary first everyone. as well

experience for total our Foreign additional of year organic EUROIMMUN organic the and approximately in driven XX% and in fourth broad-based applied and By stub X% demand exchange environment. growth growth impact XX% double-digit I’ll grew in across analytical introductions Asia, recovery China. growth points, segment, sales low in with a by XXX by organically the represented single-digit for organic in revenues, acquisitions organic X%, basis solutions of some with organic by strong health excluding represented and total offerings. an low color revenue In major fourth both to from excludes growth Discovery approximately revenue a of solid revenue product solid macro period. growth of approximately geographies growth any the adding of improving moment. the provide approximately highlighted the in approximately We organic quarter, experience X.X% with reproductive which and quarter, in growth single-digit high successful on tailwind growth new driven teen’s in points businesses of resulting genomics Brazil business and regions, healthy all we Diagnostics XXX organic a growth EUROIMMUN BRIC and represented organic revenue Americas. Europe, continued of continue basis revenue

income I’ll particularly to the upcoming have was these EUROIMMUN consolidation pension questions, available Looking the you complex period, the I’ll others. well in operating need. as change the clarify you today might further results impact prepared of tax my after provide fourth remarks, in attempt some any details impact Tom given quarter the of financials for be reform, but and at additional changes as the accounting of our for the to

schedules helpful be website In that regard. in may addition, that the on reconciliation our

were As the leverage offset XX.X% but earlier, quarter by expenses to Rob EUROIMMUN G&A, margins fourth related transaction. discussed by partially operating adjusted were driven incremental from continued

per would this $X.XX. of points. using earnings Excluding adjusted margins share quarter outstanding expanded Adjusted operating fourth approximately diluted was charge, was fully the XX for $X.XX, shares basis while per earnings XXXX basic have by share

the product of adjusted created loss charge the As we the XXXX quarter Tax R&D fourth XX%, acceleration by the use Fourth basic in a resulted calculation. which investments in per support an the share quarter, earnings Jobs which approximately of in believe the approximately earnings Act, $XXX share and Cuts XXXX million the in quarter, count per GAAP of in XX% will in share and introductions new adjusted in increase reminder, of required increased beyond. spite

Revenues and key our successful profitability deal within in further, quarter, the our franchise, Looking for forecast XXXX expectations, year by Tulip, let’s ownership the were line and quarter strength segments Asia. principally diagnostics business both Indian fourth fourth double-digits, rapid our their reproductive in revenue Europe test results screening specifically very Diagnostics. in communicable PerkinElmer prenatal health had with drivers diseases newborn of the for business with our driven by under the in growing a and exceeding growth with and driven model. start

in by to with penetrate strategy We are diagnostics XXXX we we EUROIMMUN India and beyond. For continued to be further region with positioned encouraged Made the India, opportunities within market in the well Indian collaborating in vitro the believe and our

forward at successfully now mass look NIPT launch R&D we to and Health Quad mentioned, and XXXX, business and XXXX. we a to spec diagnostics market. and Triple have Rob bring ramped As in Labs mass spending Vanadis’ Smart to Vanadis Public this spec new in Association XXXX instrument of the We the commercial recent launched

newborns tool been evidenced novel well as pleased early report are screening this We has of number for by that received a adopters. to

Vanadis at early sample validation In clinical have CE and submission for on daily activities with sites units track. remaining been collection addition, launch installed mark training,

our period Switching discovery improve exceeded expectations business, As we for our revenues the very stub strong $XX XX, transaction half and EUROIMMUN we for the slated solutions comparison for revenues as million with XXXX. environmental grew fourth pharma/biotech Asia. and expected low the approximately demand on to recall, and market of food quarter a and but product prior imaging robust close in in both by decline by demand which revenues December on well driven as are results our primarily analytical resulted recognition driven single-digit of Industry product introductions academic new organic the to stronger-than-forecasted period, in first offerings, tough services. single-digit, end low of

and franchise was the to fourth rate with in key cellular our line screening, $XX slightly below our performance ICP-OES net the services to high adjusted January our our new and XX%, growth, drivers primary environmental to focused full OneSource on quarter. year biotech expense million food was the quarter content of Switching other the below approximately interest targeting our approximately applications, for tax adjusted and analysis Looking contributors pharma items, guidance. and instrumentation and ICP-MS our

late balance the announced Turning transaction the the fourth sheet, and finished to cash. the as of EUROIMMUN $X in closed million billion quarter we and of with approximately debt year $XXX

approximately EBITDA with adjusted X.X of Our net basis, a exit we quarter times. ratio to the reported debt

operating up performance our $XX EUROIMMUN lean working solid Working as $XXX were look launch EUROIMMUN M&A, including growth, of ahead our number transaction. under we year includes our and higher that of full revenue the to royalties. divestiture cost our capital as with resulting as efficiently forecasted, of and good the related the in manage new flow look cash a initiatives operations flow XXXX, organic believe traction approximately in successful Turning closing cash strong wrap we year, of products evidenced XXXX. To capital year during the cash continuing we flow of the successful than of will we a prepaid which million to performance, by operating deal million, continue ahead Medical we’re the pleased business Imaging and but on our deals requirements from was

All to approximately of from per of this leading earnings share XX%. adjusted operations growth continuing

while believe our financial ahead better revenue strong Looking on that we for organic mission, positioned providing XXXX, to and accelerating deliver we are to results corporate growth our shareholders.

forma pro is expected basis, approximately expectations. For earnings growth year single-digit expected to revenue EUROIMMUN, million approximately with a in revenue G&A X% and of basis approximately high growth gross in guidance as to Asia. expect addition accelerating from exchange of Europe to north expect growth an on in food approximately revenue in in represents with be revenue earnings X% X%, an mentioned result XX the this XXX billion, increase points share and we a basis by per million that X% organic environmental representing on adjusted driver expansion full is adjusted our expenses, range Implicit to mid impact share be the approximately Organic base Geographically, diagnostics business Organic $X.XX revenue markets guidance EUROIMMUN. points. $XXX EUROIMMUN X%, the foreign revenue improved stable adjusted comparison. with the X% initial of $X.XX, which revenue tailwinds to in assumes organic range academic adding from basis of basis $X.XX consistent to higher operating reported EUROIMMUN. and to be margin points from R&D increase DAS industrial and XXX strong Americas gross billion revenue single-digit per organic just is a of and XX $XX in end approximately Note which includes points. and we XXXX, reported approximately mid margin growth growth of XX%, year and of growth the driven organic and of and accretion $X.XX in Full of Rob pharma growth biotech, to which is XXXX growth $X.XX in a includes

expansion our guidance basis result, XX adjusted operating approximately a points. As of XX assumes to margin

are we’re to tax terms the approximately of is of Our and incorporates borrowing tax EUROIMMUN $XXX bank from million. approximately rate, the other year financing XXX of in expected to Weighted average full guidance be approximately assumes million to our expense $XX million comprised currently XX.X%. of effective shares forecasting share related which rate EUROIMMUN net year approximately our of cost our revolver. approximately account be $XX full financing transaction million, assumptions interest and The

driven our are U.S. in and Cuts EUROIMMUN. increase XX of profits Act tax and Our rate the be effective addition current further our mix the Jobs higher and will assumptions all by rate overall the approximately expect tax effective by of points impacted jurisdictions basis Tax principally modestly we

approximately year is profit. million, EUROIMMUN’s first $XXX quarter for For Note, revenue the reported forecasting organic lowest digit represents quarter seasonally of and to that quarter the mid both first single be XXXX, which we’re revenue the of growth. revenues

of no related So the well will EUROIMMUN this due in as seasonality impact to in incremental we of terms interest from per adjusted share to expense guidance first as the earnings see impact deal. the quarter

of remarks. we’re result forecasting be adjusted per open As like at first to my $X.XX. call the up quarter a this prepared to This $X.XX the time, to for the earnings share concludes in questions. Chelsea, we range to

Operator

first Thank line you. with question [Operator the of Dan Instructions] our Thank from Citigroup. Arias And you. comes

line is Your open.

Dan Arias

the thanks. growth of the quarter. just we step Rob DAS trend guys segment should the in feel number they’re like disruptions point. this that also like upward the be you nice the end context but in the about state behind you this that How just think markets? Do up above Hey can XXXX at organizational of seem some and this X% for DAS year, given XQ

Rob Friel

Yes.

We’re of that? sort do Is so. too. we X% can than mentioned Andy possibility is a better mentioned forecasting there I previous year or think

We’re trends as out. pharma seeing pointed in good you

our in We us. good service for traction get business and food was very continue strong to

in think of low core fourth single that quarters we core well we the DAS continue sort been our of think that X%. I core The do of of the to If focus will the saw in quarter mid and be the and that XXXX of on I our the high XXXX to single-digit. of growing low-double. flat sort have challenge we businesses the actually than timeframe, quarter for first businesses are that sort better single for continue do businesses growth digits. – was couple What key the fourth businesses year So sort was in that see were in will recovered have the

Dan Arias

EUROIMMUN there to to average. the the quarter? maybe guys margin the business on revenue what And that about the get DX then you And the for growth talked ability then on Okay. was have

corporate that for Thanks. guess when we at then start investment a you So you think mean, profitability the there look this overall margin. what business point needs contributing? I to see long and the to give how should I before starts that guess to are I loft some

Rob Friel

entire continue to quarter we growth. the among disease XXXX So EUROIMMUN experience businesses and in before. they three growth good all it’s continue sort sort fairly autoimmune, high the and of growth commented based of it’s the see teen the to rate whether strong – and grow They infectious fourth broad allergy year at of

the see we’re least see go to regard volume right to immediate But up With So our excited year to ramp the the margins that approach I for there. timeframe the continue that. is of operating or the or to something EUROIMMUN we margins as for at ramp, expect we now think maybe like short-term points we’ll I a think basis XXX that. see

know to huge expectations significant years couple at of up EUROIMMUN I the least for So that margins. of ramping next don’t we’ve see got

Operator

our with of line Morgan you. question Beuchaw comes Steve the Thank And from Stanley. next

open. Your is line

Steve Beuchaw

to additions. Hi, here. divestitures Rob, of to understandably any made of an you’d not and future you’ve the we EUROIMMUN. looking really At business thanks if on like seems evolving? further terms is give questions the the very that wonder you business us the the as thinking mix. changes year much up beginner happy exiting a for your you’re How imaging that update were I taking changes in some changes big for with picked maybe times as make our sense it

Rob Friel

Okay.

the of diagnostics there. focus when all we at look expanding impact has been our sort First there of

of impact sort in our and the on I region to that to look business, just So to side diagnostic expect my alluded think of by geographic sort continue ability state. divestiture to much the I on we And wouldn’t add see I there comment. to the

the we again better business. I we I is say say I a where that’s And make you Because better. really the I in on year most the said the areas. majority focus of see Having have I think being the execute are focus amounts. how the we But we business thing should product the could significant do of lines second a majority significant is I wouldn’t could DAS invest then – dollar but is it’s But more think that the in some number. some, would wouldn’t there you the but on areas say how think opportunities. DAS growth focus do again that shut ultimately growth could during we how our see make business we that on significant

Steve Beuchaw

takes growth then strong Andy XXXX items really in the any that sense that a EUROIMMUN wonder One, for Okay. the XXXX. growth XXXX for us on might couple guidance give have the the EUROIMMUN EUROIMMUN for follow on quarter then line year just a I about margins in we appreciate it. in should of COGS And ups just And progression gross And think for impacted clarification. Rob timing there. I’ll rate the could then if in to drop. the so I you relative what rate. the from XXXX Thanks to much.

Rob Friel

the handle answer gross and can Andy that I’ll margin.

potential down a point for to over business just of possible. as been think to going from business disruption better privately has little We – our we necessarily as sort again a see prudent. before points prudent. it’s be is something is to XXXX a we the of – the growth understand or in couple just to growth it market there of we just XXX prudent call in the XX% And we’ve take don’t XX% sort think years. talked the for we’re that XX goal sort XX% going of is basis be to it given either by this rate that do suggest that of that purposes Having but forecasting disruption sort to that I amount of of at run think about we deceleration or competitive should wise anything is know would said I lower think that

Andy Wilson

mix an And question impact which services, saw than on obviously has performance. XXXX also the gross anything bit we to we Steve in have similar really period. seen contributed And gross within DAS into a throughout of mix on a the which growth wasn’t shift was margins in to margin strong have that your a and the answer margins. margin lower What diagnostics there

our XXX at prepared remarks, we should move margins we those basis in to mentioned Although, as XXXX points. that expand be gross able into we least I as think

feel So like we I think go into situating XXXX. we’re very

Operator

And the JPMorgan. Tycho line with Thank of question you. next Peterson comes our from

Your line is open.

Tycho Peterson

just build EUROIMMUN I you commercial little thanks. about out? wondering bit a Hey, on side the where in side are the that channel can if for U.S. you talk

Rob Friel

So sales them and meeting sales PerkinElmer a had between working week earlier actually we’ve this been force. U.S. and with the EUROIMMUN we force

got products. standpoint mapped forces out good other’s sales a the from both we’ve educating think each I very on plan of

think We’ve I customers place each other plans resources in accelerate of of accelerate. target. put regulatory we’ve on for provide Hopefully actually of sort products. the EUROIMMUN’s will we leads in a regard to specific got products and their approvals regulatory company good for got plan to to that the some incentive start each with required to

think of we’ve next rate accelerate couple I a or hopefully quarters. in got good the – EUROIMMUN very U.S. of the months So growth over

Tycho Peterson

And not I are you kind if levers in in about territory then into guess, X% gave you too guidance back conference or double mean far there can to the are point at here that long-term obviously diagnostics you think to of off. so the get near-term we the updated the I January digit guiding

Rob Friel

No.

be into year discussion when previous in as XX% this the the we we’ve – – it’s with continues mean to traction tool genetic finding good get course, some XX%, get of emerging I XX% from synergies levers between teens initial response some the as testing that double we talked we of what of get increasing we we number that EUROIMMUN is should like of think, we business. if And we’re get and business. digits penetrate the diagnostic start seen that to there’s of to up look able to sort XX% into got we the high a we’ve Vanadis, I get about the feel areas. if to EUROIMMUN and on

Operator

you. from comes the Donnelly Thank our line Sachs. with And next of question Patrick Goldman

line Your open. is

Patrick Donnelly

specifically on expectations I can the for What I’m of I to curious, ahead. for thanks. revenue launch appreciate know terms you year timing baked product and there color bucket in of kind XXXX. Hey just include are Vanadis in a always Vanadis revenue XQ. guys the into new

Rob Friel

I for our than It’s timing low, the is in XXXX million. at our the because for say fairly tenders plan $XX expectations Vanadis least less would of

Patrick Donnelly

Okay. maybe and I opportunity there know That’s give us it’s on how as that then on partnerships news newborn screening testing flow and early well. talked restructure an know those rare I business, And genetic on there. about you and But expectations expect we the days that in also just on should helpful. revenue testing disease update

Rob Friel

we’ve probably saying in testing, see that million to business sort particularly again China $XX think get a business into and I as areas – start And globally. that XXXX million out India point that it our next million million and been so but then $XX we out to we this intentions year to Up largely it’s to million U.S. to this by branch ramp closer can So well, think $XX are of to XXXX. genetic but call in XXXX. up other some move maybe as by $XX been to $X we business we’ll

Operator

you. comes the our of question from Thank And with Muken Ross line ISI. Evercore next

is line open. Your

Ross Muken

and Good afternoon congrats. guys

Rob Friel

Welcome back.

Ross Muken

to be you Thank Good guys. you. to talking

– environmental EUROIMMUN business talk got the obviously just as could the the are for better economy on and the through market you’re year, then moment you’ve strong both in trend industrial now show help And with double-digit business? the where – well important the there comps in understands increasingly of overall great there. you of some how obviously an correlates you of a versus secular places growth part strength. has how of that your kind sort diagnostic the terms of the sort cadence of maybe and see thinking understand So could of side So it sort China next us

Rob Friel

strong all continue us So be to first for in quarter. fourth the China of

we you EUROIMMUN sort was of I now, on think has mid-teens, say high-single it think when And in to sort particularly we right XXXX been I a the been of tenders, on. I fact in in well the the there of where we’ve China. a mainly at low where of done give seen has continued side one about side. the business in important, also our local to has diagnostic forecasting going low-double the haven’t very newborn digit is growth would see more into increasingly the look of context say some again The I the able prenatal year some newborn challenge are on little take. EUROIMMUN side. being bid strong prudent businesses, in or area we’re bit would as content particularly becoming and tenders think

I make within enthused been is China the mostly think our I And to be content the to diagnostic that our regulatory on some sort continue I the probably of reproductive to DAS assays, some of seen so got health whether be requires able to. sides. When sort businesses instruments of be diagnostic this aggressively it’s it’s side, of are months with market if to to into been requirement. some approval, fairly I side XX sort of we’ve we’ve say of non-diagnostic some And meet We’ve alluded on we manufacturing environmental, course the I think that pharmaceutical it’s able whether so side at the there moving continue opportunities now. the the the but on And local the industrial side. of on to China, go our our recovery bullish you would and sure of

think our So we’re some and I I specifically. benefits – trying that to is and markets we’re the designed sure those for make manufactured are seeing think increasingly of that products

I position it’s the it’s whether think traction functionality seeing cost the and there. or whether we’re good So

Unidentified Analyst

EUROIMMUN that growth next incremental business calc. seems counting so clarification, That’s that at two X%. component core year you’re the just Andy diagnostic Maybe for coming helpful. from one, to the in on like I guess growth just that in I the of understand core want

sure be secondarily to from And it shift the terms seasonality revenue of of then quarterly pretty of want is. normal cadence sort would Just good QX in the implies that. what think you

to of guess or out? that balance to that to of that back sort play the is fourth how it assume I seasonality going is sort quarter exactly So

Andy Wilson

second first and anomaly answer quarter. anomaly question is answer then I’ll – I’ll Yes. the just The your The the first first really second. question

are and fourth higher about the the the we’ve seasonally see, you’ll and slightly fairly for QX, third. consistent said is talked first the second QX with than quarter we being quarter and So low, year the QX as growth

The historically about split So in within points way that’s percentage about the the and related EUROIMMUN the at planning X.X XXXX. X.X%. the rate that’s to growing X% and been core is it’s we’re to business is

Rob Friel

little to very the by said Maybe doesn’t quarter rate differently growth Yes. much. way the think necessarily

the is difference the absolute low is the quarter. number The first So through consistent our is to in quarters. XX% XX% the is assumption four historically fairly

Operator

Thank from of our question you. Research. Steve next comes And Cleveland with the line Willoughby

line Your is open.

Steve Willoughby

you Hi, last year. questions. Rob taking new believe just products, sorry, good item $XX this products couple that new out from on just my if $XX then an $XX – new contributed that evening. you products in was about for as I’ve I the charge related here. it a a $XX million said revenue the just it called wasn’t One Andy headwind said million acquisition one-time on I since Thanks the think of in margins, them. quarter quarter, wondering And comp to and was are anything to to there’s why million finally that. incentive fourth with your

Rob Friel

I fourth the mix ask, attributable year million products. for we didn’t sort less so XXXX, I the although of I’ll to of of to take just through well. number we the first And It the quarters total XXs. say revenue tracking million new is a a that right, low we first $XX would then as three and we’re think good one, was were is yes, $XX the going think probably into saw in So you quarter sort the you’re

in new do I this think sort split of we and don’t products, point the at well. least we existing can Now that exclude at in another good EUROIMMUN. between the got would million products I year that would visibility as next know say but we’ve $XX revenue growth

Andy Wilson

And far to part breakout your is typically compensation then plan, can question in as the proxy. our This compensation, as a find you do not related we longer-term what of compensation. our

and So it to be out around been the box. of like the broken didn’t it’s really that’s we was operating something a part need and results that really felt in

Steve Willoughby

Okay, makes sense. Thanks

Operator

Cowen. of And our line next with you. Doug Schenkel Thank comes from question the

open. is line Your

Doug Schenkel

capital us more how an afternoon. first consistent the on that about to achieve M&A. here you today portfolio, Good and update curious question and out your specifically deployment, in I’m changing on in My the Rob. digit plans do closed you I’m on potentially recent deployment about also thinking you comments is made near-term your there guess about with I’m to thoughts repurchases. you’ve need share to curious we sit Can ability are I you now revenue And place capital long-term, give curious organic you go your EUROIMMUN. have have whether XXXX high-single growth as about

Rob Friel

acquisition. our first So deployment of strategy I all, would I know has because say changed, don’t behind the that of EUROIMMUN capital the

sort think in probably would share particular of continue bolt-on most second be below two add in capabilities would of or level others, a say would I area to let’s technological first repurchased. probably times to acquisitions And be be to the then acquisitions, EBITDA. the third preference still if that reduce either sort debt our

the on we to look acquisition, relatively that and delever we the the the believe we of we with leverage cash took the you relative at could If combination EUROIMMUN generate quickly. growth EBITDA

relative your acquisitions answer pipeline. the a to have fairly question to continue robust to So we

of currently migrate the have get I the like regard to second bigger continue And to think PerkinElmer. to sort $XXX impossible the unlikely. sort even organically that would flow cash we to say can of million a is lot diagnostics years say continue I for deals large generate. look opportunity but potential the difference We continue would and delever feel the would is the to digits a million, so we in billion million, question think to do of But I unlikely, quickly. a say we have part $XXX With at $X think north we we portfolio couple at high-single I the look portfolio as we not ability deal the to $XXX only component. of relatively to I we And doing a of be said I probably believe buy will you things. is the I short-term. if

service the be component will of think DAS I bigger.

couple DAS line. would and component as I million to I profits if in incremental major I product between helpful. can And we be let’s will food transformational say maybe bigger. think add a get of XXXX will we do But the out think we before get feel be I that a mentioned high-single now of like $XXX deal digits. don’t of growth high need the to areas, a But

our spike we’ve XX%. been into has close that As talk business of growing about XX% we past, historically to

make organically. bigger areas So the idea continue is we high-single those and invest growth in get them the digit to can

Andy Wilson

more one using Andy, the guidance. I using you other just was for your in in what FX of EUROIMMUN, in the to How rates are context – your I foreign And specifically, cover what significant in are exchange, the base guidance guess, weakening accounting calculations? in believe wanted dollar euros. EUROIMMUN of guidance? cost rates a And then context you are to thing you for Okay. pretty I FX, has

Andy Wilson

the quarter. use from consistent our Where I’ve as long ending previous we the has but been been – this rate here, we

up. quarter that going at And use of establish end rate each we an the this We’ll typically year, we the euro provide update true to for dramatically. rate, But so our into quarter the next guidance $X.XX the we strengthened that previous quarter. has as obviously which used obviously,

Operator

from Thank our you. line And next with Barclays. Meehan the Jack question comes of

open. is line Your

Jack Meehan

little just afternoon. I industrial you other caught how DAS? within in a hoping low little decline and on markets I greater could good thanks, did could and within but there? – client performance a provide – the Hi, do OneSource provide the was you singles granularity a academic, end

Rob Friel

to And is that QX? with regard

Jack Meehan

Correct, yes.

Rob Friel

Yes, okay.

and for pharma actually, low double, look areas, if a that So sort at biotech was you of us. the

as decline pleased isn’t and of sort for single. was Food the And actually Industrial was government, academic was high So it Environmental up digits of single. double us, again, digits. well. was saw to were a on We big high see step low we nice very was was single little business up. which a one bit a that. only down low

Andy Wilson

quarter, a has and in see thing which we pick by the fourth But saw up did product was pharma we driven nice lot typically the encouraging. on here in Jack, some bio, been service.

Rob Friel

Yes, service than it seen. was we’ve historically more evenly balanced and product between

Jack Meehan

rosy and I’m maybe picture. you’re And there, macroeconomic just continue for what to see the Great. Thanks. what seeing industrial itself, curious outlook XXXX too. is really on we

Rob Friel

say, saw us But little year-over-year. in industrial the difficult that we at we Americas good extent, to pretty challenged. I when Yes. I look growth was quarter would for a APAC a comparison on a side, our Europe. and fourth think, was the large

into I industrial XXXX, one. we I support think as view the it think view So be that And the continue that’s appropriate is to constructive. we continue to the project market that the believe we

Operator

comes from the our And Paul Scott. you. line next Thank of Knight question with Montgomery Janney

open. is line Your

Paul Knight

Hey, congratulations the quarter. on

Rob Friel

Thanks, Paul.

Paul Knight

size frame out incremental up there? market on your of of could specifically, this thoughts as get that my revenue? half opportunities kind percent frame of you of your the can up the you you you then Rob, And China, have read that is think pretty and of platform. platform the growth is you a big Do

Rob Friel

now, over China, to through $XXX in with right So take revenue PerkinElmer. EUROIMMUN for us will million actually,

So almost $X.X our of against XX% of and XXXX forecast revenue. it’s between billion, a XX%

earlier, side, that spending, of areas government. discussion and the important even India our it. When have a I the you the aspect becoming increasingly so disproportionate more the it’s as of that’s by you’re on the been are area when look of part Clearly, of and To population pharmaceutical at on see XX% do diagnostics diagnostics other at that was investment to as think sort where an alluded to So I mean, strategy. look environmental key those between extent, of part and think of China going we you we areas I some food, us. XX% identified of spending, that like

feel continue we So to very good.

– I invest relative the growth now. the think some down come our sort people, getting we’re But increasing China, historically, double-digit before of whether approach. such there on business prudent whether seen continue so to probably manufacturing we’re We to realistic it’s think that’s to growth bullish a bit. there, extent, low I but area little that it’s and to that in be alluded just in may fairly think it’s I that large But whether we’ve capability, I continue a to planning in the the in Chinese R&D. we

Paul Knight

lastly, DAS, go to Rob, what you you service then want to And DAS? on can you and your – you a the bit the future? something on in Where down do on want in cyclicality to – do reagents are XXXX? move by thoughts do today What do will

Rob Friel

consumable point you question try only business out, to cyclicality, higher it look the not business, part that’s as I through software a where expand hopefully an into in service very the dampens the important think more is good provide in but want our the portion technology and also or to situation increasing of DAS And the to portion the a consumable use then compared absolutely. of the But product. of service they is more and to also types time customers yes, of the the I And make measurements change Yes, we continue be service and position are to your aspect other We into improve should product. expand to services XXXX and think we down continuing we that and to of that the strategy also as But deploy as to to answer get more looking to translate outcomes to that reduces when mean, margins. do is continue our to technology customers maybe we again we’ll pull provide. believe, I way partners frame, that. absolutely. then

Operator

Derik with Thank comes of our the Bruin question America. De from Bank next you. line And of

line is open. Your

Derik De Bruin

good Hi, afternoon.

Rob Friel

afternoon. Good

Andy Wilson

afternoon. Good

Derik De Bruin

question. One So is a questions. two tax

year. XXXX? fourth So about been walk fourth sounds could budget comp the flush to like sort you’ve it’s like had you up And on on your you reforming going for of was follow-up’s some your on about a in real could headwind through talk the any quarter? I’m up. the this little what I one? stock-based bit. pretty flattish. good tax that thought you on be, that moving the then changes It would’ve Could you talk going the curious creates parts benefit comments and of just benefit the guess, sort also from quarter comments I

Andy Wilson

All right, I’ll start.

We haven’t rate real on a significant our impact the comp seen tax from piece.

As through looking my the prepared domicile we be impact up remarks, will in XXXX and our be due next into changes which mentioned my headwind, I the a is EUROIMMUN. we primarily we the in XXXX XXXX, determined and – think year that started to year went coming to that, as went mix rate and the profits real will from modest tax in to on

So a bigger what headwind Tax domicile really we profits. majority headwind a said XX.X%, the Act and and that’s on that – the of the slight on is

Rob Friel

Derik, call XX% that the have it U.S. clarify our of sort we of to revenue is maybe in XX%, help

of have U.S. the less XX% in than profit We our

Derik De Bruin

Got it.

Rob Friel

And that was of purposeful, part right.

think the sort was is So there. a if the purposefully in tax – and developed publicized often of of about highest quite put in you want to has of go one XX% you expenses been back U.S. world as lot your rate the

the our income least U.S., in of XX% than a less said, tax I from at like had, we So perspective.

And offsetting the And provisions from lower so XX% not tax the of of the impact. slightly other that rate. XX% of that rate-down have law in some significant an impact therefore, then sort of to the did are are the

Derik De Bruin

flush? budget And helpful. really that’s Okay,

Rob Friel

saw tell high I think us you saw appear single again, fourth did least It’s I bookings when quarter there in look the that was hard to some. in timeframe. in the December continued tell they’ve the at at it look when January. at of up would you strong we while sense sales But numbers pharma that The right probably now. end a we some product, up digits. and extent for the ramp we in to clearly orders was

there that is sense some flush. my So was budget

Operator

Jefferies. from our Brandon question Thank you. of the And Couillard line comes next with

is line open. Your

Brandon Couillard

afternoon. Good Thanks.

Rob Friel

Good afternoon.

Brandon Couillard

question in there then And flow quarter? EUROIMMUN In were do you fourth penciling for flow in flow one-timers the for that cash depressed one what Just conversion? free fourth you. any quarter the to cash operating closing related cash the

Andy Wilson

the million the hit that the accrued transaction, That’s related on true, fourth cost pay. deal $XX in expenses EUROIMMUN we which hit were to had quarter all – about

that I’m a about prepaid we one million as is every both those thing cash of often made obviously – sorry, on effect up go of had well, also royalty there as we flow. have so we the royalties prepaid so $X and was December addition, in dampening In the that into come

target to to for As income – continue adjusted flow try go net our we free into target. XXXX we cash one-time

that million working going hope look see to capital next you we of year. use at source about If a XXXX, a had $XX and as we into

inventory of cash feel adjusted like calculating But opportunity still And for a still on we is have the flow XX% we’re of drive income. and we of we at real what are shoot and going the kind to receivables XXX% So EUROIMMUN. net that. to impact between think we

Brandon Couillard

Very good. you. Thank

Operator

you. Bill comes the And from of question with Thank Quirk our next Piper line Jaffray.

line Your open. is

Bill Quirk

Great. Thanks. Good everybody. afternoon

Rob Friel

afternoon. Good

Bill Quirk

principal of can cover like of us Vanadis beyond anything remind questions. three like first you couple anything A Will that? menu. this Rob, or microdeletions off, just the trisomies

Rob Friel

trisomies say, I out sex So focused on, limited the initially, the particularly were going and we a of standpoint to chromosomes. from come would the menu then

X and Y. XX XX, XX, So and

of focus. we road sort initially, able Now we down the that, to think do but be the expand might that’s upon

Bill Quirk

we big unrelated And somewhat of anything Okay, then for just the to just is that then course watching be there follow-up studies got that, should China screening. over a And any are clinical in follow-up it. blood XXXX?

haven’t Thanks. a that anything while. We little about heard in

Rob Friel

half was XXXX generating quarter. hope comps the think see of are strong couple now a in to that first in something sort second on that studies maybe was So – With in regard that we earlier before, the sort particularly that want we regard of causing be blood or that screening, like data, mentioned clinical year. of of the some we are to instrument there’s had as to would the ongoing I right the placement to we difficult with in focused and

see to of the good things. reagent continue side We growth from

of see of but in So the through XXXX. placements fair impact in until or XXXX occurred a it revenue on cycle instrument the we you’ll amount the profitability, – don’t sort generates that

the So growth XXXX, business. expect I see we into better go as screening we from some to blood think

Operator

Thank Dan you. And the our Deutsche next question with line from Bank. of Leonard comes

Your line is open.

Dan Leonard

Thank you.

from XX for the understand business? So get the in a as operating of going bps the to would just of margin core addition How be much XX you’re EUROIMMUN margin the XXXX. lift to better forecast trying expansion of to expansion that operating higher-margin versus

Andy Wilson

maybe the expansion PerkinElmer. vast on basis, majority to of Well, EUROIMMUN PerkinElmer, similar the is slightly But coming an margin operating margin higher. from is core

Dan Leonard

within like And expecting Because Andy, to lot faster through diagnostics, that margin of than corporate talk core, PerkinElmer? DAS. you’re how much grow expansion a can comes about you mix

much of how that mix the So Lean some you’re and would be other versus self-help and doing? of things

Andy Wilson

Yes, Dan. think half, and probably I half it’s

Dan Leonard

Okay. much. Thank you very

Operator

of question Thank next from line Schulte Baird. you. our comes And Catherine with the

open. is line Your

Catherine Schulte

questions. Hey, for guys thanks the

course we’re a can guys have quarter launch, visibility just of any the the about from And any that Now into any you do away upcoming of timing updates over give the on year. then Vanadis the you pricing? tenders

Rob Friel

tenders yes, a good So product come with with we’ll and come to very couple half. we’re early targets release which regard fairly with tenders, specific they when more to pricing, that have pricing out, second And significant perspective sort regard countries, a on of focused the we probably mark. on which out when in we But tender, the we have after commercially, mind. some yes, so start CE

we And mark out the to QX so half get able in hopefully, to be place. CE latter the of and

of to growth I reagents, the alluded the the of will instruments back part generate think start we’ll in but in to as significant the I before, think the I be goal probably sort And XXXX. XX is eight probably to of earlier some half year.

Catherine Schulte

know versus your versus gave Thank core coming So the then give what’s bridge EPS Okay. us just can reform impact, tax a versus but And you you you. guidance, just XXXX? EUROIMMUN business I FX? from for

Andy Wilson

EUROIMMUN be XX%. And higher a Well, so reform bit for mentioned, from headwind that’s amount rate tax to coming a a the is actually of as is bit us. We as EUROIMMUN I headwind. tax little well, going has to of XX% a said a

So really at XX%, acquisition up then makes the core the is rest. the growing EUROIMMUN and about of addition

Operator

the with from comes question next Wells of our And Fargo Tim line Evans you. Securities. Thank

open. is line Your

Tim Evans

us service dollar component And then of in grew? entire fast XXXX? DAS you business about and Would be how in terms Thanks. willing the was big software tell to how that

Rob Friel

know $XXX we cut the – quarter? if it So it’s of our that don’t about about revenue. million. total, of rate don’t It’s or the about XX% necessarily probably growth in And I in the all year but together,

Tim Evans

year, In yes. the

Rob Friel

the Probably number mid-single, say, top would I don’t if I I type guess. of my know at had of to that head. probably rage, six, maybe

Tim Evans

Good enough. Thank you.

Operator

call Rob showing further I’m turn now for this time. to to remarks. closing I no And like questions would you. back the Thank at Friel

Rob Friel

Chelsea and and thank thank you, all in PerkinElmer. your of for you So questions interest

our to world. continue I ahead, doubt our mission opportunities healthier energized again to for no will year and a continue of drive we this we the to plans Looking good be updating once see on our again, customers employees to innovating by many very to have have on our our about deliver quarter. feel commitments ahead look and a you and Thanks, progress our We and terrific forward successfully moving I next shareholders. evening.

Operator

today’s for day. the may program, have all a and you gentlemen, and conclude does you Everyone, great This participating disconnect. in Ladies conference. thank

Revvity (RVTY) 25 Jan 182017 Q4 Earnings call transcript